It shows high endotoxin binding ability with little influence from the salt concentration and pH of the filtered solution!
The "Acrodisc Syringe Filter - Mustang E Membrane" is a product equipped with a membrane that has a pore size of 0.2 μm, featuring hydrophobic interaction groups and anionic exchange groups. It removes endotoxins from water, buffers, neutral sugar solutions, and some biological solutions. It demonstrates high endotoxin binding capacity with minimal influence from the salt concentration and pH of the filtered solution. 【Features】 ■ Equipped with a membrane that has a pore size of 0.2 μm, featuring hydrophobic interaction groups and anionic exchange groups ■ Removes endotoxins from water, buffers, neutral sugar solutions, and some biological solutions ■ Less affected by the salt concentration and pH of the filtered solution ■ Shows high endotoxin binding capacity *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
【Specifications (Partial)】 ■ Material Composition ・ Filter Media: Mustang E ・ Housing: Polypropylene ■ Pore Size: 0.2 μm ■ Inlet/Outlet Connection Type ・ Inlet: Female Luer Lock ・ Outlet: Male Luer Slip ■ Membrane Bed Volume: 0.12 mL ■ Maximum Operating Pressure and Temperature: 550 kPa at 21–24°C, or 210 kPa at 60°C * For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
【Application】 ■ Endotoxin removal from water, buffers, and some biomolecular samples ■ Preparation of plasmids for transfection *For more details, please refer to the PDF document or feel free to contact us.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.
